Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 75/100

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

Key Takeaway: Invivyd, Inc. will host a conference call on August 14, 2024, to discuss its second quarter 2024 financial results and business highlights. This comes after the company received emergency use authorization from the FDA for its first monoclonal antibody. Invivyd focuses on addressing serious viral infectious diseases through its proprietary INVYMAB platform, which combines viral surveillance with advanced antibody engineering. A replay of the webcast will be made available shortly after the call concludes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is hosting a conference call to discuss positive financial results.
  • The company received emergency use authorization for a monoclonal antibody.
  • Innovative approach using the INVYMAB platform for viral threats.

Full Press Release Details

WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Wednesday, August 14, 2024, at 8:30 a.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent business highlights.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Frequently Asked Questions

When is Invivyd's next conference call?

Invivyd's next conference call is on August 14, 2024, at 8:30 a.m. ET.

How can I register for the Invivyd webcast?

Listeners can register for the Invivyd webcast via a provided registration link.

What is the focus of Invivyd, Inc.?

Invivyd, Inc. specializes in protection from serious viral infectious diseases.

What platform does Invivyd use for monoclonal antibodies?

Invivyd uses the INVYMAB™ platform for developing monoclonal antibodies.

When was Invivyd's first mAb authorized?

Invivyd's first monoclonal antibody received EUA in March 2024.

Last updated: Aug 12, 2024